The prolonged fast.
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
For patients suspected of hyperinsulinism (1), whose spells eluded blood glucose documentation, provocation of symptomatic hypoglycemia by food deprivation became de rigueur once insulinoma had been identified at the Mayo Clinic in 1927 (2) as the cause of this condition. The duration of fasting varied from 12–48 h until the 1950s when investigators at the same institution recommended prolonging the fast to 72 h in the asymptomatic patient (3). In the September 2000 issue of JCEM, Hirshberg et al. (4) question the necessity for extending the period of fasting beyond 48 h in patients being evaluated for a hypoglycemic disorder. They have confirmed previous reports that most persons with insulinoma have a positive fast within 48 h. The Mayo Clinic experience of positive fasts within 48 h in large series of patients with insulinoma has been reported as: 94% (n = 108, 1927–1965) (5) and 92% (n = 51, 1964–1975) (6). In the subsequent period, 1976 to the present, we have histological confirmation in 205 patients operated on for insulinoma. Among these, 170 underwent prolonged fasts according to a standard protocol. The fast was terminated within 12 h in 33%, 24 h in 65%, 36 h in 84%, 48 h in 93%, and 72 h in 99%. Two patients had negative fasts at 72 h; in one the fast remained negative through 96 h. Although a very rare event, negative 72-h fasts in insulinoma patients have been observed by others. Could any of these prolonged fasts have been terminated earlier without sacrificing diagnostic accuracy, as suggested by Hirshberg et al. (4)? The answer to this question is predicated partly on the purpose for which the prolonged fast is conducted. When the prolonged fast is done to determine the role of β-cell polypeptides in the genesis of previously documented hypoglycemia, the fast may be terminated when the plasma glucose is 55 mg/dL or less (7) because β-cell polypeptide levels are suppressed below that glucose level. Assuming that plasma glucose is being monitored on a frequent basis, there is no good reason for a fast done for that reason to be unduly prolonged. However, recognition of this purpose for the prolonged fast is relatively new (7). The classic end point of the prolonged fast has been the demonstration of Whipple’s triad. The latter requires knowledge of the current plasma glucose concentration and identification of concurrent neuroglycopenic symptoms. The decision to end a prolonged fast requires considerable judgement by the physician in attendance and is not amenable to retrospective review, except in the rare instances of egregious inattentiveness by the responsible physician. Could the prolonged fast be arbitrarily terminated at 48 h in the asymptomatic patient and an interpretation made later based on the plasma glucose and insulin concentrations, as suggested by the NIH investigators? To do so would preclude demonstration of Whipple’s triad, an important factor in the diagnosis of a hypoglycemic disorder. In addition, although a low plasma glucose is necessary, it is not sufficient to make a diagnosis of a hypoglycemic disorder because of the overlap between normal and hypoglycemic patients (7). Furthermore, even with the use of carefully generated criteria for hyperinsulinism, plasma insulin levels fall below the criterion for hyperinsulinemia in a small number of insulinoma patients in our experience and that of the NIH group. Although the criteria for hyperinsulinemia were generated from the 72-h fast (7, 8) and apply when the plasma glucose is low regardless of the duration of food deprivation the obverse, the demonstration of β-cell suppression in the nonhypoglycemic patient probably requires 72 h of fasting to generate conditions conducive to complete β-cell suppression. It is not known whether current criteria would apply at 48 h of fasting. Since an accurate diagnosis is so important because of implications for radiologic studies (some of which may be invasive) and major surgery, we take the position of conducting evaluations with great care and measuring not only all three β-cell polypeptides (insulin, C-peptide, and proinsulin) but also insulin surrogates such as β-hydroxybutyrate and plasma glucose response to iv glucagon. We are pleased that the NIH has followed our lead in measuring plasma proinsulin directly. However, due to limitations in their analysis, which failed to relate the proinsulin concentrations to glucose concentrations in insulinoma patients vs. controls, a diagnostic criterion could not be generated by them. Recommendations regarding optimal duration of the prolonged fast based solely on experience with insulinoma fails to take into consideration that when a prolonged fast is undertaken in a patient suspected to have a hypoglycemic disorder the presence of and, indeed, the nature of that disorder is not known. For instance, in recent years we have subjected noninsulinoma hypoglycemic patients to the prolonged fast who subsequently had the following diagnoses: ins
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An occasional patient with an insulinoma may not fulfill these criteria even during a 72-h fast (15,60), and a few have plasma insulin levels below 3 U/ml (18 pmol/liter) during fasting hypoglycemia, but plasma C-peptide levels are usually 0.6 ng/ml (0.2 mmol/liter) or greater and plasma proinsulin levels are usually 5.0 pmol/liter or greater in the latter patients.”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [60]
In the citing paper
“Most, but not all (60), patients with an insulinoma fulfill these diagnostic criteria in less than 72 h.”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [60]
In the citing paper
“Indeed, that occurs in less than 24 h in about two thirds, and in less than 48 h in the vast majority, of affected patients (60).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [60]
In the citing paper
“Of note, it is helpful to know that 95% of patients with insulinoma meet end-of-fast criteria by 48 h, but the fast may be extended to 72 h as 7% of patients with proven insulinomas developed hypoglycemia after 48 h [87,88].”
From Non-Diabetic Hypoglycemia: Evaluation and Management in Adults (2025) · cites this paper as [88]
Citations
Cites
CARCINOMA OF THE ISLANDS OF THE PANCREAS: HYPERINSULINISM AND HYPOGLYCEMIA
WILDER, R. M., ALLAN, F. N., POWER, M. H., & ROBERTSON, H. E. (1927) · Journal of the American Medical Association · doi:10.1001/jama.1927.02690050014007 · Cited by 443
HYPERINSULINISM AND DYSINSULINISM
HARRIS, S. (1924) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1924.02660100003002 · Cited by 326
Service, F. J., Dale, A. J. D., Elveback, L. R., & JIANG, N.-S. (1976) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)07100-9 · Cited by 288
Self-citationForty-Eight-Hour Fast: The Diagnostic Test for Insulinoma
Hirshberg, B., Livi, A., Bartlett, D. L., Libutti, S. K., Alexander, H. R., Doppman, J. L., Skarulis, M. C., & Gorden, P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6807 · Cited by 256
(1976) · PubMed · Cited by 244
Laroche, G. P. (1968) · Archives of Surgery · doi:10.1001/archsurg.1968.01330230071009 · Cited by 77
Cited by
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1410 · Cited by 1,277
Self-citationFrancis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Diagnosis and Management of Insulinoma
Okabayashi, T. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i6.829 · Cited by 482
Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma
de Herder, W. W., Niederle, B., Scoazec, J.-Y., Pauwels, S., Klöppel, G., Falconi, M., Kwekkeboom, D. J., Öberg, K., Eriksson, B., Wiedenmann, B., et al. (2006) · Neuroendocrinology · doi:10.1159/000098010 · Cited by 295
Metadata
- Authors
- Service, F. J., & Natt, N.
- Affiliations
- Mayo Clinic (US)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-11
- Volume
- 85
- Issue
- 11
- Pages
- 3973-3974
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1991309249
- Semantic Scholar
- 1f5c44abd64ff3b333eb7256b86405b956dc9f82
- Cited by
- 168
- References
- 5
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 5 · 2020: 4 · 2019: 6 · 2018: 7 · 2017: 10 · 2016: 6 · 2015: 10 · 2014: 10 · 2013: 5 · 2012: 9
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- insulinoma, prolonged fasting, hypoglycemia, diagnostic accuracy, fasting duration, plasma glucose, Mayo Clinic history
- MeSH terms
- Blood Glucose, Diagnosis, Differential, Fasting, Humans, Hyperinsulinism, Hypoglycemia, Insulinoma, Pancreatic Neoplasms, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The prolonged fast. https://app.cochat.ai/papers/10.1210/jcem.85.11.6934
- The paper
- Service, F. J., & Natt, N. (2000). The prolonged fast. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem.85.11.6934
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.